Results 201 to 210 of about 138,877 (380)

Long‐term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236‐week, Phase 3 trial results

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
In this Phase III study, secukinumab demonstrated sustained efficacy and a favourable safety profile in paediatric patients with chronic severe plaque psoriasis over a treatment period of 236 weeks. Abstract Background Plaque psoriasis, a chronic inflammatory disease, affects up to 2.1% of the global paediatric population.
Andrzej Kaszuba   +11 more
wiley   +1 more source

Ocular cicatricial pemphigoid masquerading as chronic conjunctivitis: a case report

open access: yesClinical Ophthalmology, 2012
Joanna DaCostaMoorfields Eye Hospital, London, UKAbstract: Conjunctivitis is often considered an innocuous condition which is self-limiting. This report describes misdiagnosis of ocular cicatricial pemphigoid as chronic conjunctivitis. Ocular cicatricial
DaCosta J
doaj  

A novel MBTPS2 missense variant identifying keratosis follicularis spinulosa decalvans in a case of neonatal erythroderma

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Edwin Cuperus   +7 more
wiley   +1 more source

Efficacy of up to 4 years of tralokinumab in adults with moderate‐to‐severe atopic dermatitis

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
AD is a relapsing and remitting skin disease often requiring long‐term treatment. We assessed the long‐term efficacy of tralokinumab in adults with moderate‐to‐severe AD consistently treated for up to 4 years. Treatment with tralokinumab plus optional TCS/TCI provided substantial improvements in AD signs and symptoms, and these improvements were ...
Melinda Gooderham   +13 more
wiley   +1 more source

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault   +51 more
wiley   +1 more source

Fresh frozen plasma therapy in type I plasminogen deficiency: a case of ligneous conjunctivitis with hydrocephalus. [PDF]

open access: yesOxf Med Case Reports
AboGhayyada I   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy